The role of budesonide in controiling chest symptoms in infants was assessed. It was administered from a metered dose inhaler into a large volume spacer (Nebuhaler) system. 15 In this paper, we report the results of a double blind, crossover study investigating the effects of inhaled budesonide in wheezy infants who were less than 18 months of age.
Abstract
The role of budesonide in controiling chest symptoms in infants was assessed. It was administered from a metered dose inhaler into a large volume spacer (Nebuhaler) with attached Laerdal mask. Twenty nine infants were recruited into a double blind crossover trial. Five defaulted. The remaining 24 (mean age 11 months) were assessed for the tolerance of the device, adverse effects, treatment failures, parental opinion, and daily symptom and treatment records. Twenty tolerated the modified Nebuhaler. One developed meningitis on placebo. Two experienced exacerbations on placebo. Eleven of 18 parents whose children completed the maximum treatment preferred budesonide to placebo and one preferred placebo. Mean symptom scores on budesonide were better than on placebo for the 15 15 In this paper, we report the results of a double blind, crossover study investigating the effects of inhaled budesonide in wheezy infants who were less than 18 months of age. 
Results
Twenty nine children were enrolled into the study (table 1) . Five defaulted from follow up before completion and resisted repeated requests to reattend. This left a study group of 24 children aged 4-17 months (mean 11 months) who could be assessed.
TOLERANCE
Twenty out of the 24 children (83%) were able to tolerate the modified Nebuhaler. Three (12-5%) would only do so while asleep. Four (17%) would not even tolerate the device while asleep and could proceed no further in the trial. They were withdrawn at the end of the first three week period.
There were two treatment failures, both of whom were on placebo at the time. One of these had an exacerbation of his symptoms with an upper respiratory infection and was prescribed oral steroids by his family doctor. He showed no response to the prednisolone or subsequently to budesonide. The other child relapsed in the final period with no precipitating factors apart from the change in treatment from budesonide to placebo. He made a good recovery on restarting budesonide. One child developed Haemophilus influenzae meningitis while receiving the placebo treatment, having not previously received budesonide. He was withdrawn when diagnosis of meningitis was made.
PREFERENCE
Eighteen sets of parents (including one of the two whose children were failures on placebo treatment, and who started but failed to complete the final three weeks), were in a position to express a preference at the end of the study. Eleven (61%) preferred budesonide to placebo, and one set preferred placebo (p=0-01). Five (28%) thought that neither treatment made a difference and one (5 5%) thought both treatments were effective. There was no significant treatment order effect (period effect, p=0.8; carry over effect, p=0 5).
SYMPTOMS
Fifteen children had diaries complete enough to be suitable for analysis. Individual trends are shown in the figure. The mean total 24 hour symptom score and the mean individual symptom score parameters were better on budesonide (table 2). All symptom scores apart from nocturnal wheeze and cough showed a significant difference. This effect was also apparently independent of treatment order (period effect, p=0 4; carry over effect, p=0 5).
Less rescue bronchodilator was used while on budesonide, but as children varied in which The group of wheezy children in our study could not all necessarily be firmly classed as having asthma, and it was interesting to note the poor response of a subgroup of three children who had been ventilated in the newborn period. However, the small numbers involved make it impossible to draw any firm conclusions from this particular observation. In conclusion, for this age group of children in whom therapeutic options are limited, budesonide administered in this way offers a useful addition to the available range.
Vitamin A again One of the most exciting recent developments in paediatrics has been the realisation that giving supplements of vitamin A to young children in developing countries might prevent enormous numbers of deaths not only from measles (see Archivist 1991: 139) but from other causes.' It has been estimated that some 5-10 million children world wide develop xerophthalmia each year and between five and 10 times that number suffer from subclinical vitamin A deficiency, which leads to increased mortality from diarrhoeal and respiratory diseases. Trials of vitamin A supplementation in Indonesia2 and India3 have shown reductions in preschool child mortality of between a third and half, although another trial in India4 produced negative results. Now another trial, this time from Nepal, has produced encouraging results (Keith P West Jr and colleagues, Lancet 1991; 338: 67-71).
In all 28630 children aged between 6 months and 5 years entered the trial. They lived in 261 wards in the rural plains district of Sarlahi and each ward was allocated at random to treatment or placebo, treatment consisting of vitamin A in a dose of 60000 retinol equivalents (200 000 IU) for children of 12 months or more and half that for those less than 12 months, given every four months. Placebo consisted of vitamin A, 300 or 150 retinol equivalents according to age, also given every four months.
Over a 12 month period of follow up mortality was 16-4 per 1000 child years in the placebo group and 11-5 per 1000 child years in the vitamin A supplemented group. Supplementation, therefore, gave a 30% reduction in mortality or a protective relative risk of 017. The benefit was seen in both sexes, at all ages within the range studied, and throughout the year and it did not seem to be affected by the child's nutritional status. Significant reductions were seen for deaths attributed to measles (relative risk 0-24), non-specified infections (0-52), diarrhoea (0-61), and malnutrition (0-65) but, surprisingly, not for pneumonia.
It is estimated that vitamin A supplementation for preschool children might save over 15 000 lives in Nepal each year and about a million in the whole of south Asia. ARCHIVIST 
